Abbott Laboratories Abbott Laboratories (NYSE: ABT) isn't struggling with inflation, because its biggest customers are healthcare systems rather than consumers. And with hospitals everywhere counting on Abbott to supply diagnostic tests, medical devices, surgical tools, and branded generic medicines, it isn't about to see dropping demand anytime soon. In fact, its new glucose monitor, the FreeStyle Libre 3, is already being distributed in 60 countries less than three months from its launch in the U.S., and it's expected to be a significant driver of growth moving forward.